home / stock / tffp / tffp message board
Subject | By | Source | When |
---|---|---|---|
FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) | Paullee | investorshub | 05/01/2023 4:00:16 PM |
Well. That was interesting | derkampfer | investorshub | 02/23/2023 7:10:27 AM |
Anyone here ? Terrible conf call last night | Paullee | investorshub | 02/17/2023 2:42:41 PM |
TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to | Paullee | investorshub | 11/06/2022 2:39:18 PM |
more delays, pretty ugly out there | Paullee | investorshub | 11/02/2022 3:36:16 AM |
Yep. Just waiting on those promised deals by Glenn. | derkampfer | investorshub | 03/26/2022 4:52:44 AM |
anyone here | Paullee | investorshub | 03/17/2022 6:40:06 PM |
From Seeking Alpha | conix | investorshub | 07/27/2021 3:01:14 AM |
News, Short Squeeze, Breakout and More Instantly...
TFF Pharmaceuticals Inc - Ordinary Shares Company Name:
TFFP Stock Symbol:
NYSE Market:
New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection at 1/6 of Oral Tacrolimus Dose and with 2/3 of Oral Tacrolimus Systemic Trough Exposures...
FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology pla...
Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate Antifungal Activity and a Favorable Safety and Tolerability Profile ...